Importantly, effective therapy for MS must therefore be designed to suppress inflammation in both the spinal cord (mediated by IFN-γ signaling) and the brain (Th17/IL-17), because the specific targeting of T cells in either microenvironment may be ineffective. Here, IL17A is linked to myeloid sarcoma.